STAXYN Drug Patent Profile

✉ Email this page to a colleague

When do Staxyn patents expire, and what generic alternatives are available?

Staxyn is a drug marketed by Bayer Hlthcare and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has fifty-three patent family members in thirty-eight countries.

The generic ingredient in STAXYN is vardenafil hydrochloride. There are six drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the vardenafil hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Staxyn

A generic version of STAXYN was approved as vardenafil hydrochloride by TEVA PHARMS on May 3^rd, 2012.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for STAXYN?
What are the global sales for STAXYN?
What is Average Wholesale Price for STAXYN?

Summary for STAXYN

International Patents:	53
US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	71
Patent Applications:	4
Drug Prices:	Drug price information for STAXYN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for STAXYN
What excipients (inactive ingredients) are in STAXYN?	STAXYN excipients list
DailyMed Link:	STAXYN at DailyMed

Drug patent expirations by year for STAXYN

Paragraph IV (Patent) Challenges for STAXYN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
STAXYN	Orally Disintegrating Tablets	vardenafil hydrochloride	10 mg	200179	1	2011-12-22

US Patents and Regulatory Information for STAXYN

STAXYN is protected by one US patents.

Patents protecting STAXYN

Pharmaceutical forms with improved pharmacokinetic properties
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	STAXYN	vardenafil hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	200179-001	Jun 17, 2010		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for STAXYN

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	STAXYN	vardenafil hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	200179-001	Jun 17, 2010	⤷ Sign Up	⤷ Sign Up
Bayer Hlthcare	STAXYN	vardenafil hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	200179-001	Jun 17, 2010	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for STAXYN

See the table below for patents covering STAXYN around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Peru	131799	IMIDAZOTRIAZINONAS SUSTITUIDAS POR 2-FENILO	⤷ Sign Up
Japan	5122984		⤷ Sign Up
Russian Federation	2011111106	ЛЕКАРСТВЕННЫЕ ФОРМЫ С УЛУЧШЕННЫМИ ФАРМАКОКИНЕТИЧЕСКИМИ СВОЙСТВАМИ	⤷ Sign Up
Portugal	1049695		⤷ Sign Up
Malaysia	138535	2-PHENYL-SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS	⤷ Sign Up
South Africa	9810297	2-Phenyl-substituted imidazotriazinones	⤷ Sign Up
Finland	113772		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for STAXYN

Paragraph IV (Patent) Challenges for STAXYN

Patents protecting STAXYN

Make Better Decisions: Try a trial or see plans & pricing